In an effort to advance energy solutions and make measurable clinical and cost-of-care improvements for healthcare providers and patients globally, Ethicon*, a leading global provider of medical devices, today announced that ENSEAL X1 Large Jaw Tissue Sealer has received 510(k) clearance from the U.S. Food and Drug Administration.
The ENSEAL X1 Large Jaw Tissue Sealer is an advanced bipolar device designed to meet the needs of surgeons during open procedures such as colectomies and hysterectomies. This latest innovation from Ethicon builds upon the most comprehensive portfolio of advanced energy products from a single supplier.
The ENSEAL X1 Large Jaw Tissue Sealer represents the first in a new generation of ENSEAL technology designed to provide secure vessel sealing and precise heat management in one device with the comfort and ergonomics demanded by advanced bipolar surgeons in today’s marketplace.
“Ethicon remains committed to addressing the critical needs of patients, ensuring they have access to the most effective treatment through continued innovation and product enhancement,” says Grace Chung, Ethicon Vice President, Energy Global Strategic Marketing. “By providing access to leading-edge technology in advanced bipolar energy, we are giving hospitals the ability to work with a single advanced energy provider and surgeons increased choice and the flexibility to meet a diverse set of clinical needs for their patients and procedures.” www.ethicon.com.
*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. Ethicon Endo-Surgery, Inc. is the legal manufacturer of ENSEAL X1 Large Jaw Tissue Sealer.
(Souece: PR Newswire)